Scientists have developed an innovative method to customize and strengthen DNA origami structures, which could lead to advances in medicine, biotechnology, and beyond
Saruparib is a new-generation oral inhibitor selectively targeting PARP1. The improved safety profile can allow for more combinations to bring benefits to patients in earlier disease stages.